Protara Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-27 · Confirms TARA ticker, listed issuer name, exchange and CIK where available.SEC APISEC submissions for Protara Therapeutics, Inc.Retrieved 2026-05-27 · Company identity, filing chronology, fiscal year end, SIC description, addresses and latest filing metadata.SEC XBRL APISEC companyfacts for Protara Therapeutics, Inc.Retrieved 2026-05-27 · XBRL-derived revenue, profit, cash-flow and balance-sheet cross-checks when tagged facts are available.10-KProtara Therapeutics, Inc. annual report2026-03-10 · annual report. Used for business description, risk factors, financial statement context, governance chronology or recent event review.10-QProtara Therapeutics, Inc. latest quarterly or interim report2026-05-13 · latest quarterly or interim report. Used for business description, risk factors, financial statement context, governance chronology or recent event review.8-KProtara Therapeutics, Inc. current report2026-05-13 · current report. Used for business description, risk factors, financial statement context, governance chronology or recent event review.DEFA14AProtara Therapeutics, Inc. proxy statement2026-04-28 · proxy statement. Used for business description, risk factors, financial statement context, governance chronology or recent event review.